London
· Delayed Price · Currency is GBP · Price in USD Aclaris Therapeutics Statistics
Total Valuation
Aclaris Therapeutics has a market cap or net worth of GBP 225.86 million. The enterprise value is 86.86 million.
| Market Cap | 225.86M |
| Enterprise Value | 86.86M |
Important Dates
The next estimated earnings date is Friday, February 21, 2025.
| Earnings Date | Feb 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.48% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 74.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.15 |
| EV / Sales | 3.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.31 |
Financial Position
The company has a current ratio of 7.03, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.03 |
| Quick Ratio | 6.81 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.83% and return on invested capital (ROIC) is -26.72%.
| Return on Equity (ROE) | -25.83% |
| Return on Assets (ROA) | -19.39% |
| Return on Capital (ROIC) | -26.72% |
| Revenue Per Employee | 227,007 |
| Profits Per Employee | -310,210 |
| Employee Count | 89 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +116.38% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +116.38% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 1.70 |
| Relative Strength Index (RSI) | 42.24 |
| Average Volume (20 Days) | 5,178 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.34 |
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of GBP 20.20 million and -27.61 million in losses. Loss per share was -0.39.
| Revenue | 20.20M |
| Gross Profit | -57.39M |
| Operating Income | -46.39M |
| Pretax Income | -27.88M |
| Net Income | -27.61M |
| EBITDA | -46.41M |
| EBIT | -46.39M |
| Loss Per Share | -0.39 |
Balance Sheet
The company has 95.29 million in cash and 1.67 million in debt, giving a net cash position of 127.73 million.
| Cash & Cash Equivalents | 95.29M |
| Total Debt | 1.67M |
| Net Cash | 127.73M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 97.11M |
| Book Value Per Share | 1.36 |
| Working Capital | 84.69M |
Cash Flow
In the last 12 months, operating cash flow was -13.35 million and capital expenditures -419,308, giving a free cash flow of -13.77 million.
| Operating Cash Flow | -13.35M |
| Capital Expenditures | -419,308 |
| Free Cash Flow | -13.77M |
| FCF Per Share | n/a |
Margins
Gross margin is -284.04%, with operating and profit margins of -229.61% and -136.65%.
| Gross Margin | -284.04% |
| Operating Margin | -229.61% |
| Pretax Margin | -138.01% |
| Profit Margin | -136.65% |
| EBITDA Margin | -229.71% |
| EBIT Margin | -229.61% |
| FCF Margin | n/a |
Dividends & Yields
Aclaris Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.48% |
| Shareholder Yield | -3.48% |
| Earnings Yield | -12.22% |
| FCF Yield | -6.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aclaris Therapeutics has an Altman Z-Score of -5.06. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.06 |
| Piotroski F-Score | n/a |